Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback